The selective inhibition of cancer-associated human carbonic anhydrase (CA) enzymes, specifically CA IX and XII, has been validated as a mechanistically novel approach towards personalized cancer management. Herein we report the design and synthesis of a panel of 24 novel glycoconjugate primary sulfonamides that bind to the extracellular catalytic domain of CA IX and XII. These compounds were synthesized from variably acylated glycopyranosyl azides and either 3-or 4-ethynyl benzene sulfonamide using Cu(I)-catalyzed azide alkyne cycloaddition (CuAAC). The CA enzyme inhibition profile for all compounds was determined, while in vitro metabolic stability, plasma stability and plasma protein binding for a representative set of compounds was measured.
Introduction
There are 12 catalytically active isoforms of CA that have been characterized in humans, four of these (CA IV, IX, XII and XIV) are transmembrane anchored proteins with an extracellular active site domain. The role of CA IX and XII was recently shown to be pivotal for pH regulation to support a microenvironment suited for hypoxic tumor cell survival and proliferation through the conversion of hypoxic cell generated carbon dioxide to bicarbonate and a proton. The effect is to trap protons extracellularly and acidify the extracellular hypoxic microenvironment (supporting tumor invasiveness). HCO 3 -is transported back into the cell to maintain intracellular pH (supporting tumor cell survival). 1 The expression of CA IX and XII is upregulated in many hypoxic tumors, with CA IX usually absent in the corresponding normal tissue and CA XII constitutively expressed in a small selection of normal tissues. 2 Molecular tools that can selectively bind to or inhibit the cancerassociated CA isozymes in vivo are required to further explore the strong association between CA IX/XII expression and tumor cell survival in the altered microenvironment caused by hypoxia. CA IX-specific monoclonal antibodies are already in Phase III clinical development as both therapeutic and diagnostic agents. 3 Small molecules can provide improved pharmacokinetic profiles and lower cost over antibodies 4 and consequently we expect that small molecules which target CA IX and XII would be desirable for targeting hypoxic tumors in vivo. The membrane permeability properties of small molecules targeting CA IX and XII can in principle be employed to take advantage of the cell membrane as a barrier between off-target cytosolic CAs and transmembrane CA IX and XII. CA inhibitors with limited membrane permeability have been developed, 5 however these compounds are generally hydrophilic and so are likely to lack oral bioavailability. Esters are a common prodrug moiety employed by the pharmaceutical industry 6 and ester prodrugs of monosaccharides have been developed to mask polar hydroxyl groups with hydrophobic acyl groups as an approach to enhance oral bioavailability and enable therapeutic concentrations of the prodrug to reach the bloodstream. 7 When in the blood, the ester moiety is susceptible to hydrolysis by carboxylesterases to give the corresponding alcohol and carboxylate, potentially minimizing passive diffusion into cells within tissues.
8 Cu(I)-catalyzed azide alkyne cycloaddition (CuAAC) to synthesize triazoles has contributed to a renaissance in the chemistry of azides as building block towards higher complexity glycoconjugates. [9] [10] [11] We have recently described the synthesis of glycopyranosyl azides wherein a monosaccharide moiety was peracylated to give O-peracylated β-D-glucopyranosyl (1-5) and β-Dgalactopyranosyl azides (6-10) comprising acetyl (1 and 6) 12 , propionyl (2 and 7), butanoyl (3 and 8),
pentanoyl (4 and 9) and 3-methylbutanoyl (5 and 10) moieties. 13 We have also established that 1,2,3-triazoles are compatible with commonly employed carbohydrate protecting group approaches 14 and applied CuAAC between the O-peracylated glycopyranosyl azides and phenylacetylene to synthesize glycoconjugates as tools to study the effect of different acyl groups on biopharmaceutical properties.
We then demonstrated that these carbohydrate building blocks were susceptible to plasma hydrolytic enzymes with serial hydrolysis of the carbohydrate ester moieties to form a fully deprotected and hydrophilic glycoconjugate. Other work in our research group has applied CuAAC to synthesize CA inhibitors. 5c, 5d, 5f, 5g, 15 In the present study we combine the merits of these earlier investigations by employing the variably acylated glycopyranosyl azide building blocks 1-10 for the first time in a medicinal chemistry campaign to synthesize glycoconjugates that target CA. We assess the potential of these compounds as prodrugs for a hydrophilic glycoconjugate benzene sulfonamide compound as an approach to selectively target the active site of extracellular CA IX and XII over cytosolic CAs.
(AZA), the glycoconjugate sulfonamides 13-36 and ethynyl benzene sulfonamides 11 and 12 generally displayed poorest inhibition towards the off-target hCA I. For most glycoconjugates hCA I inhibition constants (K i ) were in the micromolar range and compounds were typically one order of magnitude weaker inhibitors of this isozyme than of hCA II, IX, XII and XIV. a Glc = glucose, Gal = galactose b Errors in the range of ± 5% of the reported value, from three determinations.
In vitro ADME. As the glucose series of compounds proved of interest with respect to SAR a representative sub-library of these compounds, 13-18, was used for in vitro biopharmaceutical property determination. We first determined the in vitro stability of the sub-library 13-18 in human plasma at 37 °C, Table 2 . The characteristic molecular weight for the potential hydrolysis intermediates and compound 13 (as a reference compound for complete hydrolysis) allowed plasma stability to be monitored using mass spectrometry, Figure 1 . Compound 13 remained stable in human plasma over the course of the incubation (4 h) indicating stability of the underlying glycoconjugate benzene sulfonamide scaffold. The acetyl, propionyl and butanoyl analogues (14, 15 and 16) were rapidly degraded with estimated half lives of 7, 3, and 25 min, respectively, while the pentanoyl (17) and the 3-methylbutanoyl (18) compounds remained stable in human plasma over the course of the incubation. The serial hydrolysis of the ester moieties to variable tri-, di-and mono-acylated ester products, respectively, formed en route to the fully hydrolysed compound 13, was confirmed by mass spectrometry, Figure 1 . We recently reported in vitro ADME properties for analogues of 13-18
that have a phenyl substituent in place of the phenyl sulfonamide substituent. 13 These compounds exhibited the same acyl group plasma stability profile with estimated half lives of 55, 26, and 555 min for the acetyl, propionyl and butanoyl analogues, respectively. The half-lives are however 8-to 25-fold longer than for the corresponding sulfonamides, meaning that the sulfonamides were more labile toward plasma esterases.
Protein binding values of the test compounds 14-18 were estimated by comparison of their chromatographic retention properties on an immobilized human serum albumin (HSA) column to those for a series of standard compounds, and indicate minimal retention of compound within the cell monolayer and minimal non-specific adsorption. For compound 15 the compound was not detected in the receptor chamber, however mass balance was poor (47%), precluding an accurate assessment of the permeability of 15, and indicating that it is possible that the compound was retained within the membrane monolayer. This result suggests that for this class of compound clogP values approaching 3 may be too high for a good passive permeability. In addition to this low concentrations of the deacylated compound (13) were detected in the donor chamber suggesting that ester hydrolysis had occurred during the experiment.
Overall these results indicate that further optimisation of the prodrug permeability properties will be needed, however the unmasked prodrug permeability is as needed to minimise off target binding to intracellular CAs. 
Conclusion
The ideal profile for an oral prodrug targeting cancer-related hCA IX and XII is good membrane permeability and poor CA inhibition, with the compound unmasked once in circulation. The unmasked compound should then exhibit the opposing characteristics of poor membrane permeability and good CA inhibition. Compounds in the glucose series of sulfonamides (13) (14) (15) (16) (17) (18) displayed the needed SAR profile to fulfill these criteria as evidenced by hCA K i values. The acetyl,
propionyl and butanoyl analogues 14-16 were degraded in human plasma and HLMs consistent with esterase processing, to form the fully deacylated compound 13 that remained stable in these environments. The propionyl analogue 15 has a cLog P value of +2.81 consistent with expected good membrane permeability while compound 13 has a cLog P value of -1.75, consistent with poor membrane permeability. The measured membrane permeability for 13 in a Caco-2 cell model confirmed negligible membrane permeability, while compound 15 may be retained in the membrane and future efforts will focus on optimizing this compound. These findings provide a beneficial guide to the impact of these acyl groups on glycoconjugate prodrug stability and performance. In conclusion, the SAR and biopharmaceutical characteristics measured for the panel of 24 glycoconjugate sulfonamides in this study highlights the potential viability of an ester-based prodrug approach to selectively target the inhibition of hCA IX and XII over off-target cytosolic CAs.
Experimental Section
General Chemistry. All starting materials and reagents, including per-O-acetylated sugars, were purchased from commercial suppliers. All solvents were available commercially dried or dried prior to use. Reaction progress was monitored by TLC using silica gel-60 F254 plates with detection by The reaction was left to stir until full deacylation was evident by TLC (CH 3 CN:H 2 O 9:1; 30 minovernight). Neutralization of the solution by Amberlite IR-120-H + ion-exchange resin, followed by filtration (the resin is washed several times with methanol) and evaporation of the filtrate to dryness, generally afforded analytically pure compounds.
4-[4''-(Aminosulfonyl)phenyl]-1-(β-D-glucopyranosyl)-1H-1,2,3-triazole (13)
The title compound 13 was prepared from compound 14 (185 mg, 0.334 mmol) according to general procedure 2 and isolated as a white solid (111 mg, 93% 
4-[3''-(Aminosulfonyl)phenyl]-1-(β-D-glucopyranosyl)-1H-1,2,3-triazole (19)
The 
4-[3''-(Aminosulfonyl)phenyl]-1-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazole (20)
The title compound 20 was prepared from glucopyranosyl azide 1 (168 mg, 0.45 mmol) and alkyne 
4-[3''-(Aminosulfonyl)phenyl]-1-(2',3',4',6'-tetra-O-propionyl-β-D-glucopyranosyl)-1H-1,2,3-triazole (21)
The title compound 21 was prepared from glucopyranosyl azide 2 (123 mg, 0.29 mmol) and alkyne 1-(2',3',4',6'-tetra-O-pentyryl-β-D-glucopyranosyl)-1H-1,2,3- 
4-[3''-(Aminosulfonyl

4-[3''-(Aminosulfonyl)phenyl]-
triazole (23)
The title compound 23 was prepared from glucopyranosyl azide 4 (142 mg, 0.260 mmol) and alkyne 
4-[4''-(Aminosulfonyl
4-[4''-(Aminosulfonyl)phenyl]-1-(2',3',4',6'-tetra-O-pentyryl-β-D-galactopyranosyl)-1H-1,2,3-triazole (29)
The title compound 29 was prepared from galactopyranosyl azide 9 (158 mg, 0.29 mmol) and alkyne 
11
4-[3''-(Aminosulfonyl)phenyl]-1-(β-D-galactopyranosyl)-1H-1,2,3-triazole (31)
The title compound 31 was prepared from triazole 32 (58 mg, 0.11 mmol) according to general procedure 2 and isolated as a white solid (38 mg, 93% concentration at which the measurement was carried out, and K m the concentration of substrate at which the enzyme activity is at half maximal.
In Vitro Metabolic Stability. Human liver microsomes (Xenotech, Tokyo, Japan) were suspended in 0.1 M phosphate buffer (pH 7.4) at a final protein concentration of 0.4 mg/mL and incubated with compounds (1 µM) at 37 °C. An NADPH-regenerating system (1 mg/mL NADP, 1 mg/mL glucose-6-phosphate, 1 U/mL glucose-6-phosphate dehydrogenase) and MgCl 2 (0.67 mg/mL) was added to initiate the metabolic reactions, which were subsequently quenched with ice-cold acetonitrile at time points ranging from 2 -60 min. Samples were also incubated in the absence of co-factor to monitor for non-cytochrome P450-mediated metabolism in the microsomal matrix. Samples were then centrifuged and the concentration of parent compound remaining in the supernatant monitored by LCMS. The first order rate constant for substrate depletion was determined by fitting the data to an exponential decay function and these values were used to calculate the in vitro intrinsic clearance (CL int ).
In Vitro Plasma Stability. Human plasma was separated from whole blood procured from the Australian Red Cross Blood Service and was stored frozen at -80 °C. On the day of the experiment, frozen plasma was thawed in a water bath maintained at 37 °C and plasma from three different donors was pooled prior to confirming plasma esterase activity by monitoring the conversion of pnitrophenyl acetate to p-nitrophenol. Each test compound was spiked into a separate aliquot of human plasma to a nominal concentration of 5000 ng/mL (final DMSO and acetonitrile concentrations were 0.2 and 0.4% (v/v), respectively). Spiked plasma was incubated at 37 °C for 4 h, and at various time points, duplicate plasma samples were taken and immediately snap-frozen in dry ice. All plasma samples were stored frozen (-20 °C) until analysis by UPLC-MS (using a Waters/Micromass Xevo triple quadrupole mass spectrometer) relative to calibration standards prepared in blank human plasma. At each sample time, the average concentration of test compound (based on duplicate samples) was expressed as a % compound remaining, and these data were used to calculate the apparent degradation half-life by fitting to an exponential decay function. The permeability of nadolol and propranolol (low and high permeability markers, respectively) was also assessed using a subset of wells from the same batch as those used to assess the test compounds.
Chromatographic
Permeability experiments were performed using Hanks balanced salt solution containing 20 mM HEPES (pH 7.4) in both the apical and basolateral chambers and permeability was assessed in the apical to basolateral direction in the absence and presence of 4% BSA in the basolateral chamber 
